Toronto, Ontario – September 27, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds (“PDCs”), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively destroy various cancers, bacteria and viruses when light or radiation activated. Theralase® announced that it has successfully completed its non-Good Laboratory Practices (“GLP”) preclinical toxicology analysis of Rutherrin® for Glio Blastoma Multiforme (“GBM”). GBM is the most aggressive and most common type of brain cancer.  The preclinical toxicology data collected to date has demonstrated that Theralase®’s Rutherrin® (RuvidarTM + human transferrin) PDC is able to be safely administered Intra Venously (“IV”) into brain cancer animal models and then successfully hunt, target and significantly accumulate inside GBM cells versus healthy brain cells. When the PDC is activated by radiation … Read More

Toronto, Ontario – August 29th, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”), their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers has released the Company’s 2Q2023 unaudited condensed interim consolidated Financial Statements (“Financial Statements”). Financial Summary: For the six-month period ended June 30th: Audited Consolidated Statements of Operations(In Canadian Dollars) 2023 2022 % Change  Revenue       Canada 305,666  426,990  -28% United States 120,421  125,452  -4% Total Revenue 426,087 552,442 -23%         Cost of Sales 224,947 271,656 -17% Gross Margin 201,140 280,786 -28% Gross Margin (% of revenue) 47% 51%           Operating Expenses       Selling Expenses 147,304 167,139 -12% Administrative Expenses 1,010,144 734,081 38% Research and Development Expenses – Device Division 25,163 105,353 -76% … Read More

Toronto, Ontario – June 6, 2023, Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce the appointment of new independent director, Kaouthar Lbiati, M.D., M.Sc. Dr. Lbiati received her Doctor of Medicine from Rabat, Morocco’s Mohammed V University and a post-doctorate in clinical oncology from Gustave Roussy Institute in Paris, which is a premier European cancer center and one of the five most prominent cancer centers in the world. She holds a specialized executive master’s degree in strategy and management from ESSEC Business School in Paris, a master’s degree in international policy and health economics from the London School of Economics, a corporate governance certification from Columbia Business School and finance … Read More

In the Performance to Primary, Secondary and Tertiary Objectives second table the 90 day results were misstated and has been corrected in this press release. Toronto, Ontario – May 30 2023, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has released the Company’s 1Q2023 unaudited condensed interim consolidated Financial Statements (“Financial Statements”). Financial Summary: For the three-month period ended March 31st: Audited Consolidated Statements of Operations             (In Canadian Dollars)     2023 2022 % Change  Revenue       Canada 152,174 179,145 -15% United States 55,037 32,517 69% Total Revenue 207,161 211,662 -2%         Cost of Sales 114,638 120,430 -4% Gross Margin 92,523 91,232 1% Gross Margin (% of revenue) 45% 43%           Operating Expenses       Selling Expenses … Read More

Toronto, Ontario – May 24, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light-activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, is pleased to announce that Roger DuMoulin-White, B.Sc., P.Eng., Pro. Dir. has been appointed as President and Chief Executive Officer (“CEO”) of the Company.   Dr. Arkady Mandel, MD, PhD, DSc has tendered his resignation as Interim CEO, but will continue to serve as Chief Scientific Officer (“CSO”) and as a member of Theralase®’s Board. Mr. DuMoulin-White is the founder of Theralase® and it’s former President and CEO.  He stepped down as President and CEO in 2018 and has since served in a non-executive business development role.  Mr. DuMoulin-White was the subject of a voluntary Settlement Agreement with the Ontario Securities Commission (“OSC”) dated February … Read More

For the primary objective, 65% of Evaluable Patients (Patients evaluated by a Principal Investigator (“PI”)) achieved a Complete Response (“CR”) at any assessment date post primary Study Treatment and 30% of Evaluable Patients achieved a CR at 450 days. Toronto, May 10, 2023 (ACCESWIRE) – Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“ PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today an update on its recently reported Phase II clinical study (“Study II”) interim clinical data. Background: Study II was designed to treat patients diagnosed with Bacillus Calmette-Guérin (“BCG”)-Unresponsive, Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) (with or without resected papillary Ta/T1 disease) with a patented investigational study drug Ruvidar™ (TLD-1433 – a ruthenium based PDC intravesically instilled … Read More

Toronto, Ontario – April 26, 2023, Theralase® Technologies Inc. (“Theralase” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers released its audited annual consolidated 2022 financial statements. Financial Summary: For the year ended December 31st: Audited Consolidated Statements of Operations             (In Canadian Dollars)    2022 2021 % Change   Revenue       Canada 1,007,841 697,727 44% United States 112,041 69,725 61% International 18,687 13,189 42% Total Revenue 1,138,569 780,641 46%         Cost of Sales 510,395 470,698 8% Gross Margin 628,174 309,943 103% Gross Margin (% of revenue) 55% 40%           Operating Expenses       Selling Expenses 301,359 363,886 -17% Administrative Expenses 1,277,253 1,562,867 -18% Research and Development Expenses – CLT Division 167,365 308,708 … Read More

Toronto, Ontario – February 23, 2023,Theralase® Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, bacteria and viruses, announced today that its Phase II clinical study (“Study II”) interim data was recently presented at the American Society of Clinical Oncology (“ASCO”) Genito Urinary (“GU”) Cancer Symposium via a moderated poster presentation. Study II has been designed to treat patients diagnosed with Bacillus Calmette-Guérin (“BCG”)-Unresponsive, Non-Muscle Invasive Bladder Cancer (“NMIBC”) Carcinoma In-Situ (“CIS”) (with or without resected papillary Ta/T1 disease) with a patented investigational study drug (TLD-1433) (Trade Name: Ruvidar™), a ruthenium based PDC intravesically instilled into a patient’s bladder, then subsequently activated by a proprietary investigational study device (TLC-3200), a green (520 nm) laser system equipped with fiber-optic light emitters … Read More